Additionally, these mutations activate tumor-associated fibroblasts (CAFs) and skew macrophages toward the M2 phenotype (TAMs), which collectively suppress T cell infiltration and function, rendering PIK3CA-targeted monotherapy ineffective clinically [13]. The gene discussed is PIK3CA; the disease is neoplasm.